%PDF-1.5% 73 0 objendobj 79 0 obj/Filter/FlateDecode/ID[]/Index[73 19]/Info 72 0 R/Length 53/Prev 51942/Root 74 0 R/Size 92/Type/XRef/W[1 2 1]stream hbbd“b`Z$C`$XÄ—#L7@k
Presenting Risk Information in Prescription Drug and Medical Device Promotion
%PDF-1.6% 2748 0 objstream hÞ¼J0_Ar4i`t]8^cHh;Û›t8PW “BB D@!50ZhulZ:RËœz{]Úˆ%MewV46sÖ»mnmQq@.(MM3Wp2NtW!M`^ã“—_!ܯ}@6Ý’=^lzOxkz^5QŪeß·Ö‡~i˯ม)QCyWR?Gx/=B^0g’C e.HA@O|vwYJÞ´hJ%]V.0(E^m));z y%9JrcL{$*2TdPNz0
Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product
%PDF-1.5% 642 0 objendobj 648 0 obj/Filter/FlateDecode/ID[]/Index[642 17]/Info 641 0 R/Length 53/Prev 138690/Root 643 0 R/Size 659/Type/XRef/W[1 2 1]stream hbbd“b`z$o@$Þ…1012 Y{
Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling
%PDF-1.5% 375 0 objendobj 389 0 obj/Filter/FlateDecode/ID[]/Index[375 27]/Info 374 0 R/Length 74/Prev 92811/Root 376 0 R/Size 402/Type/XRef/W[1 2 1]stream hbbd“b`z$; z H0$@XPÙ€,FÒˆ
Bioanalytical Method Validation [Revised Final]
%PDF-1.5% 165 0 objendobj 171 0 obj/Filter/FlateDecode/ID[]/Index[165 19]/Info 164 0 R/Length 52/Prev 124878/Root 166 0 R/Size 184/Type/XRef/W[1 2 1]stream hbbd“b` Hl@UF#iFo
Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application
%PDF-1.5% 1297 0 objendobj 1303 0 obj/Filter/FlateDecode/ID[]/Index[1297 20]/Info 1296 0 R/Length 53/Prev 124418/Root 1298 0 R/Size 1317/Type/XRef/W[1 2 1]stream hbbd“b`6 H|lǵL,F20
Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations
%PDF-1.5% 146 0 objendobj 153 0 obj/Filter/FlateDecode/ID[]/Index[146 20]/Info 145 0 R/Length 56/Prev 169540/Root 147 0 R/Size 166/Type/XRef/W[1 2 1]stream hbbd“b`6!@Ľ$ؾ
Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment
%PDF-1.5% 99 0 objendobj 105 0 obj/Filter/FlateDecode/ID[]/Index[99 17]/Info 98 0 R/Length 52/Prev 80125/Root 100 0 R/Size 116/Type/XRef/W[1 2 1]stream hbbd“b`:$C+`v@;#’#1Æ”
Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment
%PDF-1.6% 141 0 objendobj 148 0 obj/Filter/FlateDecode/ID[]/Index[141 20]/Info 140 0 R/Length 55/Prev 259003/Root 142 0 R/Size 161/Type/XRef/W[1 2 1]stream hbbd“b`^$@3{HM
Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment
%PDF-1.5% 203 0 objendobj 210 0 obj/Filter/FlateDecode/ID[]/Index[203 20]/Info 202 0 R/Length 57/Prev 195825/Root 204 0 R/Size 223/Type/XRef/W[1 2 1]stream hbbd“b`@HÓ€D Q-RH@